logo
Plus   Neg
Share
Email

Marriott Posts Adj. Loss In Q2; Revenue Down 72%

Marriott International, Inc. (MAR) reported a second quarter adjusted loss per share of $0.64, compared to profit of $1.56, previous year. The second quarter adjusted results included impairment charges and bad debt expense of $0.17 per share, related to COVID-19. On average, 22 analysts polled by Thomson Reuters expected the company to report a loss per share of $0.42, for the quarter. Analysts' estimates typically exclude special items. Adjusted EBITDA was $61 million, compared to $952 million, previous year. Second quarter 2020 adjusted EBITDA included $36 million of bad debt expense related to COVID-19.

Second quarter total revenues were $1.46 billion, down 72 percent from a year ago. Analysts expected revenue of $1.68 billion for the quarter. Comparable systemwide constant dollar RevPAR declined 84.4 percent worldwide, 83.6 percent in North America and 86.7 percent outside North America.

Arne Sorenson, CEO of Marriott, said, "While our business continues to be profoundly impacted by COVID-19, we are seeing steady signs of demand returning. Worldwide RevPAR has climbed steadily since its low point of down 90 percent for the month of April, to a decline of 70 percent for the month of July. Worldwide occupancy rates, which bottomed at 11 percent for the week ended April 11, have improved each week, reaching nearly 34 percent for the week ended August 1."

As of the end of the second quarter, the company's net liquidity totaled approximately $4.4 billion, representing roughly $2.3 billion in cash and cash equivalents, and $2.9 billion of unused borrowing capacity under revolving credit facility, less $0.8 billion of commercial paper outstanding.

Shares of Marriott were down nearly 3% in pre-market trade on Monday.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The U.S. Food and Drug Administration on Saturday authorized Johnson & Johnson's (JNJ) single-dose COVID-19 vaccine for emergency use. It is the first single-shot COVID-19 vaccine and the third COVID-19 vaccine for emergency use in the U.S. - the other two being Pfizer/BioNTech's BNT162b2 and Moderna's mRNA-1273. The U.S. Food and Drug Administration said that it will rapidly work toward finalization and issuance of an emergency use authorization of Johnson & Johnson's (JNJ) single-shot COVID-19 vaccine candidate. Billionaire Warren Buffett's Berkshire Hathaway Inc. (BRK.A, BRK.B) reported that its fourth-quarter net earnings attributable to shareholders rose 23 percent to $35.84 billion from last year's $29.16 billion, with earnings per share improving to $23,015 per Class A share from $17,909 per Class A share in the prior year.
Follow RTT